Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.
Bamias A, Zakopoulou R, Tzannis K, Sakellakis M, Koutsoukos K, Kyriazoglou A, Panagiotou A, Armylagos S, Rokas K, Gotzias D, Boulouta A, Bozionelou V, Stravodimos K, Varkarakis I, Mavroudis D, Dimopoulos MA.
Bamias A, et al. Among authors: sakellakis m.
Anticancer Drugs. 2023 Mar 1;34(3):413-421. doi: 10.1097/CAD.0000000000001420. Epub 2022 Nov 16.
Anticancer Drugs. 2023.
PMID: 36730619
Clinical Trial.